32797-61-8

Basic information

• Product Name: 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE
• Synonyms: 4-AMINOMETHYL BENZAMIDINE, 2HCL;4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE;4-Aminomethyl-benzamidine
• CAS NO: 32797-61-8
• Molecular Formula: C₈H₁₁N₃
• Molecular Weight: 222.11
• Mol File: 32797-61-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 283.8°C at 760 mmHg
• Flash Point: 125.5°C
• Appearance: /
• Vapor Pressure: 0.00309mmHg at 25°C
• CAS DataBase Reference: 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE(32797-61-8)
• EPA Substance Registry System: 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE(32797-61-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 32797-61-8(Hazardous Substances Data)

Usage

Description

4-Aminomethyl benzamidine dihydrochloride, also known as B5775, is a water-soluble chemical compound with the molecular formula C8H13Cl2N3. It is typically found as a white crystalline powder and is widely used in scientific and industrial applications, particularly in biochemistry. 4-AMINOMETHYL BENZAMIDINE DIHYDROCHLORIDE is recognized for its function as a damnacanthal mimetic and as an inhibitor of kinases and proteases, making it a valuable component in various research activities.

Uses

Used in Biochemical Research:
4-Aminomethyl benzamidine dihydrochloride is used as a research compound for its ability to mimic damnacanthal and inhibit the activity of kinases and proteases. This makes it a valuable tool in studying the mechanisms of these enzymes and their roles in various biological processes.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-Aminomethyl benzamidine dihydrochloride is used as a starting material or intermediate in the synthesis of potential drug candidates. Its properties as an enzyme inhibitor can be leveraged to develop new therapeutic agents targeting specific kinases or proteases, which are often implicated in various diseases.
Used in Chemical Synthesis:
4-Aminomethyl benzamidine dihydrochloride is employed as a reagent in the synthesis of other chemical compounds. Its unique structure and reactivity make it a useful building block in the creation of more complex molecules, which can be applied in various fields, including materials science and specialty chemicals.

InChI:InChI=1/C8H11N3.2ClH/c9-5-6-1-3-7(4-2-6)8(10)11;;/h1-4H,5,9H2,(H3,10,11);2*1H

Upstream product

• 162696-15-3 N-Boc-4-aminomethyl benzamidine 
• 66389-80-8 tert-butyl N-[(4-cyanophenyl)methyl]carbamate 
• 63914-51-2 [(4-cyanophenyl)methyl]-carbamic acid phenylmethyl ester 
• 17201-43-3 4-cyanobenzyl bromide 
• 84466-87-5 4-(azidomethyl)benzonitrile 
• 10406-25-4 4-aminobenzyl cyanide 
• 328552-93-8 4-(aminomethyl)-N-hydroxybenzene-1-carboximidamide 
• 366023-02-1 (4-carbamimidoyl-benzyl)-carbamic acid benzyl ester 

Downstream Products

• 1456890-24-6 N-(4-carbamimidoylbenzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide 
• 1449371-73-6 C₁₄H₁₂N₆O₃ 
• 1449371-69-0 C₂₁H₂₀N₆O₃S 
• 1449371-67-8 C₁₆H₁₈N₆O₃S 
• 1449371-68-9 C₂₇H₂₅N₁₁O₄S 
• 1449371-74-7 C₂₀H₂₂N₄O₂S 

Relevant articles and documents

Protein-Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background-Free Amidation Reaction

Protein-templated reactions enable the target-guided formation of protein ligands from reactive fragments, ideally with no background reaction. Herein, we investigate the templated formation of amides. A nucleophilic fragment that binds to the coagulation factor Xa was incubated with the protein and thirteen differentially activated dipeptides. The protein induced a non-catalytic templated reaction for the phenyl and trifluoroethyl esters; the latter was shown to be a completely background-free reaction. Starting from two fragments with millimolar affinity, a 29 nm superadditive inhibitor of factor Xa was obtained. The fragment ligation reaction was detected with high sensitivity by an enzyme activity assay and by mass spectrometry. The reaction progress and autoinhibition of the templated reaction by the formed ligation product were determined, and the structure of the protein–inhibitor complex was elucidated.

Thrombin inhibitors having a lactam at P3

The present invention provides compounds having a lactam ring at P3 and at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.

Non-covalent inhibitors of urokinase and blood vessel formation

Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have Pi a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.